8-K: Aurinia Reports Strong 2025 LUPKYNIS Sales, Issues 2026 Guidance

Aurinia Pharmaceuticals announced robust financial results for Q4 and full-year 2025, driven by significant LUPKYNIS sales growth, and provided optimistic 2026 revenue guidance.

Summary

• Total revenue for the three months ended December 31, 2025, was $77.1 million, a 29% increase from $59.9 million in the same period of 2024.
• Total revenue for the twelve months ended December 31, 2025, was $283.1 million, a 20% increase from $235.1 million in the same period of 2024.
• Net product sales of LUPKYNIS for the three months ended December 31, 2025, were $74.2 million, up 29% from $57.6 million in the prior year.
• Net product sales of LUPKYNIS for the twelve months ended December 31, 2025, were $271.3 million, up 25% from $216.2 million in the prior year.
• Net income for the three months ended December 31, 2025, was $210.8 million, a 14957% increase from $1.4 million in the prior year, primarily due to a $175.1 million income tax benefit.
• Net income for the twelve months ended December 31, 2025, was $287.2 million, a 4852% increase from $5.8 million in the prior year, primarily due to a $173.0 million income tax benefit.
• Diluted earnings per share for the three months ended December 31, 2025, was $1.53, up 15200% from $0.01 in the prior year.
• Diluted earnings per share for the twelve months ended December 31, 2025, was $2.07, up 5075% from $0.04 in the prior year.
• Cash flows from operating activities for the twelve months ended December 31, 2025, were $135.7 million, a 206% increase from $44.4 million in the prior year.
• As of December 31, 2025, cash, cash equivalents, restricted cash, and investments totaled $398.0 million, compared to $358.5 million at December 31, 2024.
• The company repurchased 12.2 million common shares for $98.2 million during the year ended December 31, 2025.
• For 2026, Aurinia expects total revenue of $315 million to $325 million, representing an 11% to 15% increase compared to 2025.
• For 2026, Aurinia expects net product sales of LUPKYNIS of $305 million to $315 million, representing a 12% to 16% increase compared to 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, driven by strong LUPKYNIS sales, significant profitability improvements (even with the tax benefit), robust cash generation, and optimistic 2026 guidance, alongside pipeline advancement.

Positives

• Strong LUPKYNIS net product sales growth of 29% in Q4 2025 and 25% for the full year 2025.
• Significant increase in net income and diluted EPS, driven by a substantial income tax benefit from the release of a valuation allowance on deferred tax assets.
• Robust cash flows from operating activities, increasing by 206% for the full year 2025 to $135.7 million.
• Healthy cash position with $398.0 million in cash, cash equivalents, restricted cash, and investments as of December 31, 2025.
• Execution of a share repurchase program, buying back 12.2 million common shares for $98.2 million in 2025.
• Positive 2026 guidance projecting continued double-digit growth in total revenue (11-15%) and net product sales (12-16%).
• Advancement of aritinercept, a dual BAFF/APRIL inhibitor, with a clinical study initiated in one autoimmune disease and plans to initiate another in the first half of 2026.

Negatives

• License, collaboration, and royalty revenue decreased by 38% for the full year 2025 to $11.7 million, primarily due to a $10.0 million milestone payment associated with LUPKYNIS regulatory approval in Japan in 2024 not recurring in 2025.

Risks

• Risks and uncertainties associated with LUPKYNIS net product sales.
• Risks and uncertainties related to the timing of clinical study results.
• General risks and uncertainties identified in the company's filings with the U.S. Securities and Exchange Commission, including the most recent Annual Report on Form 10-K.

Future Outlook

Aurinia projects 2026 total revenue to be between $315 million and $325 million, an increase of 11% to 15% over 2025, with LUPKYNIS net product sales expected to be $305 million to $315 million, representing a 12% to 16% increase. The company plans to continue increasing LUPKYNIS adoption and advancing aritinercept, with a new clinical study for an additional autoimmune disease slated for the first half of 2026.

Management Comments

• "We are pleased to have delivered strong LUPKYNIS sales growth in 2025."
• "We expect 2026 to be an exciting year for Aurinia."
• "We remain focused on increasing LUPKYNIS adoption among lupus nephritis patients and advancing aritinercept, a dual BAFF/APRIL inhibitor, which has the potential to treat a wide range of autoimmune diseases."
• "We have initiated a clinical study of aritinercept in one autoimmune disease and plan to initiate a clinical study in an additional autoimmune disease in the first half of 2026."

Industry Context

StockSavvy.ai notes that Aurinia's strong LUPKYNIS sales growth and positive outlook for 2026 position it favorably within the competitive autoimmune disease market. The advancement of aritinercept into multiple clinical studies indicates a strategic focus on pipeline expansion, crucial for long-term growth in the biopharmaceutical sector where innovation drives market share and addresses unmet medical needs.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, share repurchases, and positive future guidance, potentially leading to increased share value.
• Patients (Lupus Nephritis): Continued focus on LUPKYNIS adoption suggests ongoing access and support for patients with high unmet medical needs.
• Employees: Continued growth and pipeline development may indicate job stability and potential for growth within the company.
• Creditors: Improved cash flow and financial health enhance the company's ability to meet its obligations.

Next Steps

• Increase LUPKYNIS adoption among lupus nephritis patients.
• Advance aritinercept development.
• Initiate a clinical study of aritinercept in an additional autoimmune disease in the first half of 2026.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with significant revenue and net product sales growth for LUPKYNIS, a substantial increase in net income and EPS (even accounting for the tax benefit), and robust cash flow generation. The positive 2026 guidance and advancement of the aritinercept pipeline further strengthen the company's future prospects. The share repurchase program also indicates management's confidence. These factors collectively suggest a strong investment opportunity.

Keywords

Aurinia Pharmaceuticals, AUPH, LUPKYNIS, lupus nephritis, autoimmune diseases, financial results, earnings, revenue, net product sales, 2026 guidance, aritinercept, biopharmaceutical, Q4 2025, full year 2025